徐艺硕,胡思宁,贾海波,于波

• 1:哈尔滨医科大学附属第二医院心内科

摘要(Abstract)：

对梗死相关冠状动脉行早期直接经皮冠状动脉介入治疗（PPCI）是指南推荐治疗急性ST段抬高型心肌梗死（STEMI）的常规手段，可以有效减少心肌梗死面积并保留左心室收缩功能。尽管PPCI可以成功恢复心外膜冠状动脉血流，但仍有部分患者因微循环功能障碍无法实现最佳心肌灌注并影响远期预后。因此，及时评估STEMI患者微循环功能并采取相应治疗策略至关重要。本文针对冠状动脉微循环侵入性诊断技术及治疗策略用于STEMI患者的最新研究进展进行综述。

关键词(KeyWords)： 急性ST段抬高型心肌梗死;冠状动脉微循环;微循环功能障碍

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划资助项目（2016YFC1301104）;国家重点研发计划资助项目（2016YFC1301100）

作者(Author): 徐艺硕,胡思宁,贾海波,于波

参考文献(References)：

• [1] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2019,40(2):87-165.
• [2] Niccoli G, Montone RA, Ibanez B, et al. Optimized treatment of ST-elevation myocardial infarction[J]. Cir Res,2019,125(2):245-258.
• [3] de Waha S, Patel MR, Granger CB, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction:an individual patient data pooled analysis from seven randomized trials[J]. Eur Heart J, 2017,38(47):3502-3510.
• [4] Caixeta A, Lansky AJ, Mehran R, et al. Predictors o f suboptimal TIMI flow after primary angioplasty for acute myocardial infarction:results from the HORIZONS-AMI trial[J]. EuroIntervention, 2013,9(2):220-227.
• [5] Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades，fl ow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction[J]. Circulation,2002,105(16):1909-1913.
• [6] Porto I, Burzotta F, Brancati M, et al. Relation o f myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention[J]. Am J Cardiol, 2007,99(12):1671-1673.
• [7] van T Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction:myocardial blush grade[J]. J Am Coll Cardiol, 1998,97(23):2302-2306.
• [8] Sharma V, Jolly SS, Hamid T, et al. Myocardial blush and microvascular reperfusion following manual thrombectomy during percutaneous coronary intervention for ST elevation myocardial infarction:insights from the TOTAL trial[J].Eur Heart J, 2016,37(24):1891-1898.
• [9] Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction[J]. J Am Coll Cardiol, 2002,39(4):591-597.
• [10] Ding S, Pu J, Qiao Z, et al. TIMI myocardial perfusion frame count:a new method to assess myocardial perfusion and its predictive value for short-term prognosis[J]. Catheter Cardiovasc Interv, 2010,75(5):722-732.
• [11] Haeck JD, Gu YL, Vogelzang M, et al. Feasibility and applicability of computer-assisted myocardial blush quantifi cation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Catheter Cardiovasc Interv, 2010,75(5):701-706.
• [12] Vogelzang M, Vlaar PJ, Svilaas T, et al. Computer-assisted myocardial blush quantification after percutaneous coronary angioplasty for acute myocardial infarction:a substudy from the TAPAS trial[J]. Eur Heart J, 2009,30(5):594-599.
• [13] Everaars H, de Waard GA, Driessen RS, et al. Doppler fl ow velocity and thermodilution to assess coronary flow reserve:a head-to-head comparison with[15O]H2O PET[J]. JACC Cardiovasc Interv. 2018,11(20):2044-2054.
• [14] Hassell MECJ, Bax M, van Lavieren MA, et al.Microvascular dysfunction following ST-elevation myocardial infarction and its recovery over time[J]. EuroIntervention.2017,13(5):e578-e584.
• [15] van de Hoef TP, Bax M, Meuwissen M, et al. Impact of coronary microvascular function on long-term cardiac mortality in patients with acute st-segment–elevation myocardial infarction[J]. Cir Cardiovasc Interv, 2013,6(3):207-215.
• [16] Qi Y, Gu R, Xu J, et al. Index of microcirculatory resistance predicts long term cardiac systolic function in patients with STEMI undergoing primary PCI[J]. BMC Cardiovasc Disord, 2021,21(1):66.
• [17] Maznyczka AM, Oldroyd KG, Greenwood JP, et al.Comparative signifi cance of invasive measures of microvascular injury in acute myocardial infarction[J]. Cir Cardiovasc Interv,2020,13(5):e8505.
• [18] De Mar ia GL, Alkhal il M, Wolfrum M, et al.I n d e x of microcirculatory resistance as a tool to characterize microvascular obstruction and to predict infarct size regression in patients with STEMI undergoing primary PCI[J]. JACC Cardiovasc Imaging, 2019,12(5):837-848.
• [19] Scarsini R, Shanmuganathan M, De Maria GL, et al.Coronary microvascular dysfunction assessed by pressure wire and CMR after STEMI predicts long-term outcomes[J]. JACC Cardiovasc Imaging,2021,14(10):1948-1959.
• [20] Choi KH, Dai N, Li Y, et al. Functional coronary angiography-derived index of microcirculatory resistance in patients with st-segment elevation myocardial infarction[J].JACC Cardiovasc Interv, 2021,14(15):1670-1684.
• [21] Scarsini R, De Maria GL, Borlotti A, et al. Incremental value of coronary microcirculation resistive reserve ratio in predicting the extent of myocardial infarction in patients with STEMI. Insights from the oxford acute myocardial infarction(OxAMI)Study[J]. Cardiovasc Revasc Med,2019,20(12):1148-1155.
• [22] de Waard GA, Fahrni G, de Wit D, et al. Hyperaemic microvascular resistance predicts clinical outcome and microvascular injury after myocardial infarction[J]. Heart,2018,104(2):127-134.
• [23] Teunissen PF, de Waard GA, Hollander MR, et al.Doppler-derived intracoronary physiology indices predict the occurrence of microvascular injury and microvascular perfusion defi cits after angiographically successful primary percutaneous coronary intervention[J]. Cir Cardiovasc Interv, 2015,8(3):e001786.
• [24] Nanto S, Masuyama T, Takano Y, et al. Determination of coronary zero fl ow pressure by analysis of the baseline pressureflow relationship in humans[J]. Jpn Circ J,2001,65(9):793-796.
• [25] Patel N, Petraco R, Dall’Armellina E, et al. Zero-flow pressure measured immediately after primary percutaneous coronary intervention for st-segment elevation myocardial infarction provides the best invasive index for predicting the extent of myocardial infarction at 6 months[J]. JACC Cardiovasc Interv, 2015,8(11):1410-1421.
• [26] Niccoli G, Rigattieri S, De Vita MR, et al. Open-label,randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction[J].JACC Cardiovasc Interv, 2013,6(6):580-589.
• [27] Mahaf fey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction:results of a multicenter, randomized, placebocontrolled trial:the acute myocardial infarction study of adenosine(AMISTAD)trial[J]. J Am Coll Cardiol,1999,34(6):1711-1720.
• [28] Ross AM, Gibbons RJ, Stone GW, et al. A randomized,double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction(AMISTAD-Ⅱ)[J]. J Am Coll Cardiol, 2005,45(11):1775-1780.
• [29] Nazir SA, McCann GP, Greenwood JP, et al. Strategies to attenuate micro-vascular obstruction during P-PCI:the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial[J]. Eur Heart J,2016,37(24):1910-1919.
• [30] Aetesam-Ur-Rahman M, Brown AJ, Jaworski C, et a l. Adenosine-induced coronary steal is observed in patients presenting with ST-segment-elevation myocardial infarction[J]. J Am Heart Assoc, 2021,10(13):e19899.
• [31] Stone GW. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction[J].JAMA, 2012,307(17):1817-1826.
• [32] Eitel I, W?hrle J, Suenkel H, et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol, 2013,61(13):1447-1454.
• [33] Piccolo R, Eitel I, Galasso G, et al. 1-Year outcomes with intracoronary abciximab in diabetic patients undergoing primary percutaneous coronary intervention[J]. J Am Coll Cardiol,2016,68(7):727-738.
• [34] Zhu TQ, Zhang Q, Qiu JP, et al. Beneficial effects o f intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention:the ICT-AMI study[J]. Int J Cardiol,2013,165(3):437-443.
• [35] Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2006,68(5):671-676.
• [36] Wang L, Cheng Z, Gu Y, et al. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon:a meta-analysis of randomized controlled trials[J]. Biomed Res Int, 2015,2015:1-7.
• [37]郭丽霞，张兰，姜潇思，等.尼可地尔预处理对非ST段抬高型急性冠状动脉综合征患者无复流现象的预防效果[J].中国介入心脏病学杂志，2019,27(3):140-144.
• [38]王苏，孟晶晶，王茜，等.心肌核素显像指导下尼可地尔治疗冠状动脉慢血流1例[J].中国介入心脏病学杂志，2018,26(12):717-718.
• [39] Kostic J, Djordjevic-Dikic A, Dobric M, et al. The ef fects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI[J].Cardiovasc Ultrasound, 2015,13(1):26.
• [40] Niu X, Zhang J, Bai M, et al. Ef fect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction:a network meta-analysis[J]. BMC Cardiovasc Disord, 2018,18(1):3.
• [41] McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction[J]. JAMA, 2019,321(1):56.
• [42] McCartney PJ, Maznyczka AM, Eteiba H, et al. Low-dose alteplase during primary percutaneous coronary intervention according to ischemic time[J]. J Am Coll Cardiol, 2020,75(12):1406-1421.
• [43] Luo D, Hu X, Sun S, et al. The outcomes in STEMI patients with high thrombus burden treated by deferred versus immediate stent implantation in primary percutaneous coronary intervention:a prospective cohort study[J]. Ann Transl Med,2021,9(7):573.
• [44] Kim JS, Lee HJ, Woong Yu C, et al. INNOVATION Study(impact of immediate stent implantation versus deferred stent implantation on infarct size and microvascular perfusion in patients with ST-segment-elevation myocardial infarction)[J]. Cir Cardiovasc Interv, 2016,9(12):e004101.
• [45] Kelb?k H, H?fsten DE, K?ber L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction(DANAMI 3-DEFER):an open-label, randomised controlled trial[J]. Lancet, 2016,387(10034):2199-2206.
• [46]董海萌，于波.急性ST段抬高型心肌梗死行血栓抽吸的相关研究进展[J].中国介入心脏病学杂志，2020,28(4):219-223.
• [47]刘海伟，王效增，荆全民，等.血栓抽吸后行直接冠状动脉支架置入术对急性ST段抬高心肌梗死患者的疗效观察[J].中国介入心脏病学杂志，2016,24(11):646-650.
• [48] Jolly SS, Cairns JA, Yusuf S, et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction:1-year follow-up of the prospective randomised TOTAL trial[J]. Lancet, 2016,387(10014):127-135.
• [49] Jolly SS, Cairns JA, Lavi S, et al. Thrombus aspiration in patients with high thrombus burden in the TOTAL Trial[J]. J Am Coll Cardiol, 2018,72(14):1589-1596.
• [50] Jolly SS, James S, D?avík V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction[J]. Circulation,2017,135(2):143-152.
• [51] Teramoto R, Sakata K, Miwa K, et al. Impact of distal protection with filter-type device on long-term outcome after percutaneous coronary intervention for acute myocardial infarction:clinical results with filtrap[J]. J Atheroscler Thromb, 2016, 23(12):1313-1323.
• [52] Hibi K, Kozuma K, Sonoda S, et al. A randomized study of distal filter protection versus conventional treatment during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound[J]. JACC Cardiovasc Interv, 2018,11(16):1545-1555.
• [53] Hibi K, Kozuma K, Maejima N, et al. Long-term clinical outcomes after filter protection during percutaneous coronary intervention in patients with attenuated plaque-1-year follow up of the VAMPIRE 3(vacuum aspiration thrombus reemoval 3)trial[J]. Circ J,2020,85(1):44-49.